Home - ClinicalTrials.gov · 8 9 7.6.1 Adverse Events. 7.6.1.1 Adverse Events of Special Importance...
33
Transcript of Home - ClinicalTrials.gov · 8 9 7.6.1 Adverse Events. 7.6.1.1 Adverse Events of Special Importance...
![Page 1: Home - ClinicalTrials.gov · 8 9 7.6.1 Adverse Events. 7.6.1.1 Adverse Events of Special Importance 7.6.1.2 Clinical Laboratory Parameters 7.6.2 ECOG Performance Status.. 7.6.3 Concomitant](https://reader034.fdocuments.in/reader034/viewer/2022050112/5f49a589e0aceb2f0a188043/html5/thumbnails/1.jpg)
![Page 2: Home - ClinicalTrials.gov · 8 9 7.6.1 Adverse Events. 7.6.1.1 Adverse Events of Special Importance 7.6.1.2 Clinical Laboratory Parameters 7.6.2 ECOG Performance Status.. 7.6.3 Concomitant](https://reader034.fdocuments.in/reader034/viewer/2022050112/5f49a589e0aceb2f0a188043/html5/thumbnails/2.jpg)
![Page 3: Home - ClinicalTrials.gov · 8 9 7.6.1 Adverse Events. 7.6.1.1 Adverse Events of Special Importance 7.6.1.2 Clinical Laboratory Parameters 7.6.2 ECOG Performance Status.. 7.6.3 Concomitant](https://reader034.fdocuments.in/reader034/viewer/2022050112/5f49a589e0aceb2f0a188043/html5/thumbnails/3.jpg)
![Page 4: Home - ClinicalTrials.gov · 8 9 7.6.1 Adverse Events. 7.6.1.1 Adverse Events of Special Importance 7.6.1.2 Clinical Laboratory Parameters 7.6.2 ECOG Performance Status.. 7.6.3 Concomitant](https://reader034.fdocuments.in/reader034/viewer/2022050112/5f49a589e0aceb2f0a188043/html5/thumbnails/4.jpg)
![Page 5: Home - ClinicalTrials.gov · 8 9 7.6.1 Adverse Events. 7.6.1.1 Adverse Events of Special Importance 7.6.1.2 Clinical Laboratory Parameters 7.6.2 ECOG Performance Status.. 7.6.3 Concomitant](https://reader034.fdocuments.in/reader034/viewer/2022050112/5f49a589e0aceb2f0a188043/html5/thumbnails/5.jpg)
![Page 6: Home - ClinicalTrials.gov · 8 9 7.6.1 Adverse Events. 7.6.1.1 Adverse Events of Special Importance 7.6.1.2 Clinical Laboratory Parameters 7.6.2 ECOG Performance Status.. 7.6.3 Concomitant](https://reader034.fdocuments.in/reader034/viewer/2022050112/5f49a589e0aceb2f0a188043/html5/thumbnails/6.jpg)
![Page 7: Home - ClinicalTrials.gov · 8 9 7.6.1 Adverse Events. 7.6.1.1 Adverse Events of Special Importance 7.6.1.2 Clinical Laboratory Parameters 7.6.2 ECOG Performance Status.. 7.6.3 Concomitant](https://reader034.fdocuments.in/reader034/viewer/2022050112/5f49a589e0aceb2f0a188043/html5/thumbnails/7.jpg)
![Page 8: Home - ClinicalTrials.gov · 8 9 7.6.1 Adverse Events. 7.6.1.1 Adverse Events of Special Importance 7.6.1.2 Clinical Laboratory Parameters 7.6.2 ECOG Performance Status.. 7.6.3 Concomitant](https://reader034.fdocuments.in/reader034/viewer/2022050112/5f49a589e0aceb2f0a188043/html5/thumbnails/8.jpg)
![Page 9: Home - ClinicalTrials.gov · 8 9 7.6.1 Adverse Events. 7.6.1.1 Adverse Events of Special Importance 7.6.1.2 Clinical Laboratory Parameters 7.6.2 ECOG Performance Status.. 7.6.3 Concomitant](https://reader034.fdocuments.in/reader034/viewer/2022050112/5f49a589e0aceb2f0a188043/html5/thumbnails/9.jpg)
![Page 10: Home - ClinicalTrials.gov · 8 9 7.6.1 Adverse Events. 7.6.1.1 Adverse Events of Special Importance 7.6.1.2 Clinical Laboratory Parameters 7.6.2 ECOG Performance Status.. 7.6.3 Concomitant](https://reader034.fdocuments.in/reader034/viewer/2022050112/5f49a589e0aceb2f0a188043/html5/thumbnails/10.jpg)
![Page 11: Home - ClinicalTrials.gov · 8 9 7.6.1 Adverse Events. 7.6.1.1 Adverse Events of Special Importance 7.6.1.2 Clinical Laboratory Parameters 7.6.2 ECOG Performance Status.. 7.6.3 Concomitant](https://reader034.fdocuments.in/reader034/viewer/2022050112/5f49a589e0aceb2f0a188043/html5/thumbnails/11.jpg)
![Page 12: Home - ClinicalTrials.gov · 8 9 7.6.1 Adverse Events. 7.6.1.1 Adverse Events of Special Importance 7.6.1.2 Clinical Laboratory Parameters 7.6.2 ECOG Performance Status.. 7.6.3 Concomitant](https://reader034.fdocuments.in/reader034/viewer/2022050112/5f49a589e0aceb2f0a188043/html5/thumbnails/12.jpg)
![Page 13: Home - ClinicalTrials.gov · 8 9 7.6.1 Adverse Events. 7.6.1.1 Adverse Events of Special Importance 7.6.1.2 Clinical Laboratory Parameters 7.6.2 ECOG Performance Status.. 7.6.3 Concomitant](https://reader034.fdocuments.in/reader034/viewer/2022050112/5f49a589e0aceb2f0a188043/html5/thumbnails/13.jpg)
![Page 14: Home - ClinicalTrials.gov · 8 9 7.6.1 Adverse Events. 7.6.1.1 Adverse Events of Special Importance 7.6.1.2 Clinical Laboratory Parameters 7.6.2 ECOG Performance Status.. 7.6.3 Concomitant](https://reader034.fdocuments.in/reader034/viewer/2022050112/5f49a589e0aceb2f0a188043/html5/thumbnails/14.jpg)
![Page 15: Home - ClinicalTrials.gov · 8 9 7.6.1 Adverse Events. 7.6.1.1 Adverse Events of Special Importance 7.6.1.2 Clinical Laboratory Parameters 7.6.2 ECOG Performance Status.. 7.6.3 Concomitant](https://reader034.fdocuments.in/reader034/viewer/2022050112/5f49a589e0aceb2f0a188043/html5/thumbnails/15.jpg)
![Page 16: Home - ClinicalTrials.gov · 8 9 7.6.1 Adverse Events. 7.6.1.1 Adverse Events of Special Importance 7.6.1.2 Clinical Laboratory Parameters 7.6.2 ECOG Performance Status.. 7.6.3 Concomitant](https://reader034.fdocuments.in/reader034/viewer/2022050112/5f49a589e0aceb2f0a188043/html5/thumbnails/16.jpg)
![Page 17: Home - ClinicalTrials.gov · 8 9 7.6.1 Adverse Events. 7.6.1.1 Adverse Events of Special Importance 7.6.1.2 Clinical Laboratory Parameters 7.6.2 ECOG Performance Status.. 7.6.3 Concomitant](https://reader034.fdocuments.in/reader034/viewer/2022050112/5f49a589e0aceb2f0a188043/html5/thumbnails/17.jpg)
![Page 18: Home - ClinicalTrials.gov · 8 9 7.6.1 Adverse Events. 7.6.1.1 Adverse Events of Special Importance 7.6.1.2 Clinical Laboratory Parameters 7.6.2 ECOG Performance Status.. 7.6.3 Concomitant](https://reader034.fdocuments.in/reader034/viewer/2022050112/5f49a589e0aceb2f0a188043/html5/thumbnails/18.jpg)
![Page 19: Home - ClinicalTrials.gov · 8 9 7.6.1 Adverse Events. 7.6.1.1 Adverse Events of Special Importance 7.6.1.2 Clinical Laboratory Parameters 7.6.2 ECOG Performance Status.. 7.6.3 Concomitant](https://reader034.fdocuments.in/reader034/viewer/2022050112/5f49a589e0aceb2f0a188043/html5/thumbnails/19.jpg)
![Page 20: Home - ClinicalTrials.gov · 8 9 7.6.1 Adverse Events. 7.6.1.1 Adverse Events of Special Importance 7.6.1.2 Clinical Laboratory Parameters 7.6.2 ECOG Performance Status.. 7.6.3 Concomitant](https://reader034.fdocuments.in/reader034/viewer/2022050112/5f49a589e0aceb2f0a188043/html5/thumbnails/20.jpg)
![Page 21: Home - ClinicalTrials.gov · 8 9 7.6.1 Adverse Events. 7.6.1.1 Adverse Events of Special Importance 7.6.1.2 Clinical Laboratory Parameters 7.6.2 ECOG Performance Status.. 7.6.3 Concomitant](https://reader034.fdocuments.in/reader034/viewer/2022050112/5f49a589e0aceb2f0a188043/html5/thumbnails/21.jpg)
![Page 22: Home - ClinicalTrials.gov · 8 9 7.6.1 Adverse Events. 7.6.1.1 Adverse Events of Special Importance 7.6.1.2 Clinical Laboratory Parameters 7.6.2 ECOG Performance Status.. 7.6.3 Concomitant](https://reader034.fdocuments.in/reader034/viewer/2022050112/5f49a589e0aceb2f0a188043/html5/thumbnails/22.jpg)
![Page 23: Home - ClinicalTrials.gov · 8 9 7.6.1 Adverse Events. 7.6.1.1 Adverse Events of Special Importance 7.6.1.2 Clinical Laboratory Parameters 7.6.2 ECOG Performance Status.. 7.6.3 Concomitant](https://reader034.fdocuments.in/reader034/viewer/2022050112/5f49a589e0aceb2f0a188043/html5/thumbnails/23.jpg)
![Page 24: Home - ClinicalTrials.gov · 8 9 7.6.1 Adverse Events. 7.6.1.1 Adverse Events of Special Importance 7.6.1.2 Clinical Laboratory Parameters 7.6.2 ECOG Performance Status.. 7.6.3 Concomitant](https://reader034.fdocuments.in/reader034/viewer/2022050112/5f49a589e0aceb2f0a188043/html5/thumbnails/24.jpg)
![Page 25: Home - ClinicalTrials.gov · 8 9 7.6.1 Adverse Events. 7.6.1.1 Adverse Events of Special Importance 7.6.1.2 Clinical Laboratory Parameters 7.6.2 ECOG Performance Status.. 7.6.3 Concomitant](https://reader034.fdocuments.in/reader034/viewer/2022050112/5f49a589e0aceb2f0a188043/html5/thumbnails/25.jpg)
![Page 26: Home - ClinicalTrials.gov · 8 9 7.6.1 Adverse Events. 7.6.1.1 Adverse Events of Special Importance 7.6.1.2 Clinical Laboratory Parameters 7.6.2 ECOG Performance Status.. 7.6.3 Concomitant](https://reader034.fdocuments.in/reader034/viewer/2022050112/5f49a589e0aceb2f0a188043/html5/thumbnails/26.jpg)
![Page 27: Home - ClinicalTrials.gov · 8 9 7.6.1 Adverse Events. 7.6.1.1 Adverse Events of Special Importance 7.6.1.2 Clinical Laboratory Parameters 7.6.2 ECOG Performance Status.. 7.6.3 Concomitant](https://reader034.fdocuments.in/reader034/viewer/2022050112/5f49a589e0aceb2f0a188043/html5/thumbnails/27.jpg)
![Page 28: Home - ClinicalTrials.gov · 8 9 7.6.1 Adverse Events. 7.6.1.1 Adverse Events of Special Importance 7.6.1.2 Clinical Laboratory Parameters 7.6.2 ECOG Performance Status.. 7.6.3 Concomitant](https://reader034.fdocuments.in/reader034/viewer/2022050112/5f49a589e0aceb2f0a188043/html5/thumbnails/28.jpg)
![Page 29: Home - ClinicalTrials.gov · 8 9 7.6.1 Adverse Events. 7.6.1.1 Adverse Events of Special Importance 7.6.1.2 Clinical Laboratory Parameters 7.6.2 ECOG Performance Status.. 7.6.3 Concomitant](https://reader034.fdocuments.in/reader034/viewer/2022050112/5f49a589e0aceb2f0a188043/html5/thumbnails/29.jpg)
![Page 30: Home - ClinicalTrials.gov · 8 9 7.6.1 Adverse Events. 7.6.1.1 Adverse Events of Special Importance 7.6.1.2 Clinical Laboratory Parameters 7.6.2 ECOG Performance Status.. 7.6.3 Concomitant](https://reader034.fdocuments.in/reader034/viewer/2022050112/5f49a589e0aceb2f0a188043/html5/thumbnails/30.jpg)
![Page 31: Home - ClinicalTrials.gov · 8 9 7.6.1 Adverse Events. 7.6.1.1 Adverse Events of Special Importance 7.6.1.2 Clinical Laboratory Parameters 7.6.2 ECOG Performance Status.. 7.6.3 Concomitant](https://reader034.fdocuments.in/reader034/viewer/2022050112/5f49a589e0aceb2f0a188043/html5/thumbnails/31.jpg)
![Page 32: Home - ClinicalTrials.gov · 8 9 7.6.1 Adverse Events. 7.6.1.1 Adverse Events of Special Importance 7.6.1.2 Clinical Laboratory Parameters 7.6.2 ECOG Performance Status.. 7.6.3 Concomitant](https://reader034.fdocuments.in/reader034/viewer/2022050112/5f49a589e0aceb2f0a188043/html5/thumbnails/32.jpg)
![Page 33: Home - ClinicalTrials.gov · 8 9 7.6.1 Adverse Events. 7.6.1.1 Adverse Events of Special Importance 7.6.1.2 Clinical Laboratory Parameters 7.6.2 ECOG Performance Status.. 7.6.3 Concomitant](https://reader034.fdocuments.in/reader034/viewer/2022050112/5f49a589e0aceb2f0a188043/html5/thumbnails/33.jpg)